Seprafilm Slurry in the Prevention of Uterine Scarring in Patients Undergoing Hysteroscopic Myomectomy (Seprafilm)
The Role of Seprafilm Bioresorbable Slurry in the Prevention of Intrauterine Synechiae in Patients Undergoing Hysteroscopic Myomectomy
Sponsor: Genzyme, a Sanofi Company
Terminated
No subjects were recruited at the Weill Cornell site.
Other terminated trials from Genzyme, a Sanofi Company
A PHASE4 clinical study on Intrauterine Adhesions, this trial is terminated or withdrawn. The trial is conducted by Genzyme, a Sanofi Company and has accumulated 8 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE4
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE4
Status: Unknown Status → Terminated
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE4
First recorded
May 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genzyme, a Sanofi Company
- Weill Medical College of Cornell University
For direct contact, visit the study record on ClinicalTrials.gov .